ESC 2024 | SCOFF Trial: Fasting or No Fasting before Cardiac Catheterization Procedures

Millions of people undergo either diagnostic or therapeutic coronary procedures that require sedation. The aim of this study was to assess whether food restriction is necessary before sedation in these procedures. 

This was a randomized study in centers of Australia. Patients were randomly assigned 1:1 to two groups: the fasting group (6 hours with no solid food and 2 without any liquids) and the no restriction group (habitual diet).

The primary outcome was a composite of events including aspiration pneumonia, hypotension, hyper and hypo glycaemia. 

716 patients were included, mean age 69, 35% women. Primary end point occurred in 19.1% of the fasting group and 12% of the regular diet group. Upon intention to treat analysis, the net difference was -5.2% in favor of the no fast group, confirming non inferiority for this strategy.

Read also: ESC 2024 | SENIOR RITA: Invasive Strategy for Elderly Patients with ACS.

As regards patient satisfaction, it was significantly higher in the no fast group (15±4.3 vs. 11±4.0 satisfaction).

This study, together with the CHOW-NOW, TONIC and Fast-CIED studies, shows there is solid evidence in favor of the lack of benefit of fasting prior these kind of procedures. 

Presented by David Ferreia at Hot-Line Sessions, ESC Congress 2024, August 30 thru September 2, London, England  


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...